Back to articles

Reduction in heart failure associated with dapagliflozin use


Use of dapagliflozin (Farxiga—AstraZeneca) in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular (CV) disease resulted in a significant reduction in the risk of CV death or hospitalization for heart failure compared with placebo. However, it did not significantly reduce the risk of major adverse CV events (MACE), according to results of the DECLARE-TIMI 58 trial published in the New England Journal of Medicine.


Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE–TIMI). N Engl J Med. 2018;[Epub ahead of print].